Sensex, Nifty Trim Losses; ONGC & IndusInd Bank Top Losers

Fri, 12 Jun 12:30 pm

   Previous Close   

   Pre-Open   

   09:30 am   

   02:30 pm   

   Closing   

Share markets in India climbed off the day's low but are still trading over 1% lower.

Benchmark indices tumbled in the opening trade today, following US and Asian peers that fell amid worries over resurgence in Covid cases and a gloomy economic projection.

The US Federal Reserve released a gloomy economic outlook at the end of its two-day monetary policy meeting on Wednesday. Chairman Jerome Powell warned of a "long road" to recovery.

Wall Street plummeted with all three major US stock indexes losing over 5%, posting their worst one-day percentage drops since March 16, when markets were sent into freefall by the abrupt economic lockdowns put in place to contain the pandemic.

The Nasdaq snapped its three-day streak of record closing highs.

The BSE Sensex is trading down by 456 points (down 1.4%), at 33,100 levels.

Meanwhile, the NSE Nifty is trading down by 135 points (down 1.4%).

The BSE Mid Cap index and the BSE Small Cap index are trading down by 0.8% and 1.3%, respectively.

Sectoral indices are trading on a negative note with stocks in the IT sector and banking sector witnessing most of the selling pressure.

The rupee is trading at Rs 75.94 against the US$.

In news from the commodity space, domestic gold prices fell sharply today after rallying in the previous session. On MCX, August gold futures fell 0.7% to Rs 47,065 per 10 gram after a Rs 800 rally in the previous session.

Tracking gold, silver futures on MCX tumbled Rs 850 to Rs 47,805 per kg. In the previous session, silver had rallied over 1%.

In global markets, gold prices were flat today as a stronger US dollar offset rising safe-haven demand amid gloomy economic projections and renewed fears over a second wave in coronavirus cases.

Global gold rates have rallied about 20% since touching an over three-month low of US$ 1,451 in mid-March.

Meanwhile, the third tranche of sovereign gold bonds of this fiscal, which opened for subscription on Monday, closes today.

The issue price for the same has been fixed at Rs 4,677 per gram.

We will keep you updated on how gold performs in the coming days. Stay tuned.

Speaking of gold, how lucrative has gold been as a long-term investment in India?

The chart below shows the annual returns on gold over the last 15 years...

Gold Has Been a Shining Long-Term Investment

As you can see, barring just two years - 2013 and 2015, gold has delivered positive returns in 13 of the last 15 years.

Here's what we wrote about this in one of the editions of The 5 Minute WrapUp...

• In fact, gold has delivered double-digit gains in 10 of the last 15 years.
  
  During the entire 15-year period, gold has shot up 555% (compounded annual return of 12.1%).
  
  During the same period, the Sensex surged 511% (compounded annual return of 12.0%). If you include dividends, the Sensex returns would be higher than gold by a couple of percentage points.
  
  One must note that the Sensex returns are not representative of the broader market returns. Moreover, gold was a no-brainer. You didn't have to study financial statements, business models and forecast future earnings growth to get a double-digit return on your investment.

In one of his videos, Vijay Bhambwani, editor of Fast Profits Daily explains why this year's US presidential elections could be bullish for gold.

As per him, the US presidential cycle may not be as predictable this time as it usually is. But there is good money to be made if you can play this trend correctly.

He shows a simple way to profit from this important event. Tune in to know more...

Moving on to news from the pharma sector, Biocon today said that its biosimilar insulin glargine, co-developed with Mylan, has been approved by the US Food and Drug Administration (USFDA).

The regulator has given nod to the insulin, Semglee, in vial and pre-filled pen format to control high blood sugar in both Type 1 and Type 2 diabetes patients.

This is the third Biocon-Mylan biosimilar to be approved in the US market after fulphila and trastuzumab, both used for treating cancer patients.

Reports state that USFDA's nod to Semglee, which already has approval in 45 countries, gives a boost to Biocon's ambitious target of US$ 1 billion in sales through its biologics division by FY22.

During the fourth quarter of FY20 (Q4FY20), this segment had reported a de-growth of 21% because of Covid-19 impact after reporting three consecutive quarters of robust performance.

Note that the company has also committed to provide affordable insulin at Rs 7 per day to lower and middle income countries as compared to Rs 350 per day currently.

Biocon share price is presently trading down by 0.5%.

Speaking of the pharma sector, in December 2019, co-head of Research at Equitymaster, Tanushree Banerjee had predicted that pharma could be the sector to see a big rebound in 2020.

And rightly so, most pharma companies have re-emerged as the safer bets for investors in the ongoing market turmoil.

In April, the Indian rupee touched a new record low of Rs 76.92 against the US dollar. Most pharma companies generate their revenues through exports. Hence, a depreciating rupee is a positive development for them.

As per Tanushree, in a post Covid-19 world, healthcare expenditures globally will see a big rejig.

Tanushree has her eyes on an exciting tech stock. The company in question is developing its medical division. It's focusing on telemedicine, which Tanushree believes will be a huge growth driver in a post Corona world.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers